The ethical case for placebo control in HIV-cure-related studies with ART interruption

Many studies that seek to cure HIV must ask participants to interrupt their antiretroviral treatment. In such circumstances, is it permissible to include a placebo group in the study? We explain why doing so is a scientific and an ethical necessity, and more benign than imagined.

Detalles Bibliográficos
Autores principales: Magalhaes, Monica, Kuritzkes, Daniel R., Eyal, Nir
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9464947/
https://www.ncbi.nlm.nih.gov/pubmed/36106155
http://dx.doi.org/10.1016/j.jve.2022.100084
Descripción
Sumario:Many studies that seek to cure HIV must ask participants to interrupt their antiretroviral treatment. In such circumstances, is it permissible to include a placebo group in the study? We explain why doing so is a scientific and an ethical necessity, and more benign than imagined.

Ejemplares similares